(Total Views: 153)
Posted On: 07/29/2024 10:48:06 AM
Post# of 1460
Below copied from IHUB… Just maybe we are getting closer to seeing our Anavex approved,
Fletch
falconer66a
Re: plexrec post# 465356
Monday, July 29, 2024 10:02:49 AM
Post# of 465434
When Useful, Will Post on Anavex Science
falconer---care to chime in ?? Yesterday's Presentation ??????
I’ve restrained my postings in recent months (regarding blarcamesine, Anavex, etc.). Those familiar with my postings know that I have a rather complete understanding of the cellular physiology of the mechanisms of actions (MOAs) of the Anavex sigma-1 receptor activators. So very different from and so far more effective than the MAB (monoclonal antibody) competitors; and are more easily administered (orally), without AEs, adverse events; side effects. No brain hemorrhaging, no brain shrinkage. And more.
In anticipation of this presentation, a week ago I expanded my AVXL position. Had some discretionary dollars; which with my now slightly larger AVXL position have appreciated nicely — a share price gain that I contend will continue in the following weeks and months. Then, application for blarcamesine approval in the EMA. With that, future AVXL price appreciations will no longer be speculation. Schizophrenia approval will follow; will be BIG.
All of the usual AVXL naysayers are working hard at their keyboards to post reasons why, once again, as always before, Anavex will fail. I’m not going to waste my time trying negate their quasi-scientific Anavex naysayings. The “market” will prevail. Will be interested to see what the real investment experts, at the New York Times, for example, will be saying. Will general news media have stories to the effect, “New Drug Candidate Gives Real Hope for Alzheimer’s?” Should they appear, how will the public react to such news articles?
We’ll all be watching. When there’s some science I can usefully comment on, I’ll post it. Until then, I and my few AVXL friends will privately share our understandings. Things Anavex coming together just as expected.
https://investorshub.advfn.com/Anavex-Life-Sc...AVXL-11474
Fletch
falconer66a
Re: plexrec post# 465356
Monday, July 29, 2024 10:02:49 AM
Post# of 465434
When Useful, Will Post on Anavex Science
falconer---care to chime in ?? Yesterday's Presentation ??????
I’ve restrained my postings in recent months (regarding blarcamesine, Anavex, etc.). Those familiar with my postings know that I have a rather complete understanding of the cellular physiology of the mechanisms of actions (MOAs) of the Anavex sigma-1 receptor activators. So very different from and so far more effective than the MAB (monoclonal antibody) competitors; and are more easily administered (orally), without AEs, adverse events; side effects. No brain hemorrhaging, no brain shrinkage. And more.
In anticipation of this presentation, a week ago I expanded my AVXL position. Had some discretionary dollars; which with my now slightly larger AVXL position have appreciated nicely — a share price gain that I contend will continue in the following weeks and months. Then, application for blarcamesine approval in the EMA. With that, future AVXL price appreciations will no longer be speculation. Schizophrenia approval will follow; will be BIG.
All of the usual AVXL naysayers are working hard at their keyboards to post reasons why, once again, as always before, Anavex will fail. I’m not going to waste my time trying negate their quasi-scientific Anavex naysayings. The “market” will prevail. Will be interested to see what the real investment experts, at the New York Times, for example, will be saying. Will general news media have stories to the effect, “New Drug Candidate Gives Real Hope for Alzheimer’s?” Should they appear, how will the public react to such news articles?
We’ll all be watching. When there’s some science I can usefully comment on, I’ll post it. Until then, I and my few AVXL friends will privately share our understandings. Things Anavex coming together just as expected.
https://investorshub.advfn.com/Anavex-Life-Sc...AVXL-11474
(1)
(0)Scroll down for more posts ▼
